S&P 500   3,900.79 (-0.58%)
DOW   31,253.13 (-0.75%)
QQQ   289.58 (-0.54%)
AAPL   137.35 (-2.46%)
MSFT   253.14 (-0.37%)
FB   191.29 (-0.49%)
GOOGL   2,207.68 (-1.35%)
AMZN   2,146.38 (+0.19%)
TSLA   709.42 (-0.05%)
NVDA   171.24 (+1.10%)
BABA   87.69 (+0.44%)
NIO   16.66 (+5.24%)
AMD   96.67 (+0.41%)
CGC   5.87 (+5.01%)
MU   69.40 (-2.32%)
T   20.21 (-0.10%)
GE   75.74 (+0.72%)
F   12.85 (+0.55%)
DIS   103.14 (-1.11%)
AMC   13.08 (+2.51%)
PFE   50.65 (+0.50%)
PYPL   81.28 (+5.31%)
NFLX   183.48 (+3.55%)
S&P 500   3,900.79 (-0.58%)
DOW   31,253.13 (-0.75%)
QQQ   289.58 (-0.54%)
AAPL   137.35 (-2.46%)
MSFT   253.14 (-0.37%)
FB   191.29 (-0.49%)
GOOGL   2,207.68 (-1.35%)
AMZN   2,146.38 (+0.19%)
TSLA   709.42 (-0.05%)
NVDA   171.24 (+1.10%)
BABA   87.69 (+0.44%)
NIO   16.66 (+5.24%)
AMD   96.67 (+0.41%)
CGC   5.87 (+5.01%)
MU   69.40 (-2.32%)
T   20.21 (-0.10%)
GE   75.74 (+0.72%)
F   12.85 (+0.55%)
DIS   103.14 (-1.11%)
AMC   13.08 (+2.51%)
PFE   50.65 (+0.50%)
PYPL   81.28 (+5.31%)
NFLX   183.48 (+3.55%)
S&P 500   3,900.79 (-0.58%)
DOW   31,253.13 (-0.75%)
QQQ   289.58 (-0.54%)
AAPL   137.35 (-2.46%)
MSFT   253.14 (-0.37%)
FB   191.29 (-0.49%)
GOOGL   2,207.68 (-1.35%)
AMZN   2,146.38 (+0.19%)
TSLA   709.42 (-0.05%)
NVDA   171.24 (+1.10%)
BABA   87.69 (+0.44%)
NIO   16.66 (+5.24%)
AMD   96.67 (+0.41%)
CGC   5.87 (+5.01%)
MU   69.40 (-2.32%)
T   20.21 (-0.10%)
GE   75.74 (+0.72%)
F   12.85 (+0.55%)
DIS   103.14 (-1.11%)
AMC   13.08 (+2.51%)
PFE   50.65 (+0.50%)
PYPL   81.28 (+5.31%)
NFLX   183.48 (+3.55%)
S&P 500   3,900.79 (-0.58%)
DOW   31,253.13 (-0.75%)
QQQ   289.58 (-0.54%)
AAPL   137.35 (-2.46%)
MSFT   253.14 (-0.37%)
FB   191.29 (-0.49%)
GOOGL   2,207.68 (-1.35%)
AMZN   2,146.38 (+0.19%)
TSLA   709.42 (-0.05%)
NVDA   171.24 (+1.10%)
BABA   87.69 (+0.44%)
NIO   16.66 (+5.24%)
AMD   96.67 (+0.41%)
CGC   5.87 (+5.01%)
MU   69.40 (-2.32%)
T   20.21 (-0.10%)
GE   75.74 (+0.72%)
F   12.85 (+0.55%)
DIS   103.14 (-1.11%)
AMC   13.08 (+2.51%)
PFE   50.65 (+0.50%)
PYPL   81.28 (+5.31%)
NFLX   183.48 (+3.55%)
NASDAQ:ATRA

Atara Biotherapeutics (ATRA) Stock Forecast, Price & News

$5.16
+0.03 (+0.58%)
(As of 05/19/2022 04:00 PM ET)
Add
Compare
Today's Range
$5.00
$5.35
50-Day Range
$5.00
$9.84
52-Week Range
$4.84
$20.04
Volume
1.30 million shs
Average Volume
1.01 million shs
Market Capitalization
$481.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.92
30 days | 90 days | 365 days | Advanced Chart
Receive ATRA News and Ratings via Email

Sign-up to receive the latest news and ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Atara Biotherapeutics logo

About Atara Biotherapeutics

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATRA
Fax
N/A
Employees
578
Year Founded
N/A

Sales & Book Value

Annual Sales
$20.34 million
Book Value
$3.16 per share

Profitability

Net Income
$-340.14 million
Net Margins
-1,451.79%
Pretax Margin
-1,672.05%

Debt

Price-To-Earnings

Miscellaneous

Free Float
89,857,000
Market Cap
$481.97 million
Optionable
Optionable

Company Calendar

Last Earnings
5/05/2022
Today
5/19/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.74 out of 5 stars

Medical Sector

866th out of 1,418 stocks

Biological Products, Except Diagnostic Industry

133rd out of 210 stocks

Analyst Opinion: 3.4Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -













Atara Biotherapeutics (NASDAQ:ATRA) Frequently Asked Questions

Is Atara Biotherapeutics a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Atara Biotherapeutics stock.
View analyst ratings for Atara Biotherapeutics
or view top-rated stocks.

When is Atara Biotherapeutics' next earnings date?

Atara Biotherapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Atara Biotherapeutics
.

How were Atara Biotherapeutics' earnings last quarter?

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) issued its quarterly earnings data on Thursday, May, 5th. The biotechnology company reported ($0.87) EPS for the quarter, beating the consensus estimate of ($0.98) by $0.11. Atara Biotherapeutics had a negative net margin of 1,451.79% and a negative trailing twelve-month return on equity of 113.94%. During the same quarter last year, the company earned ($0.86) EPS.
View Atara Biotherapeutics' earnings history
.

What price target have analysts set for ATRA?

5 brokers have issued 12 month price targets for Atara Biotherapeutics' stock. Their forecasts range from $8.00 to $67.00. On average, they expect Atara Biotherapeutics' stock price to reach $32.67 in the next twelve months. This suggests a possible upside of 533.1% from the stock's current price.
View analysts' price targets for Atara Biotherapeutics
or view top-rated stocks among Wall Street analysts.

Who are Atara Biotherapeutics' key executives?
Atara Biotherapeutics' management team includes the following people:
  • Dr. Pascal Touchon D.V.M., Pres, CEO & Director (Age 59, Pay $1.09M)
  • Mr. Utpal Koppikar M.B.A., Exec. VP & CFO (Age 51, Pay $655.45k) (LinkedIn Profile)
  • Mr. Joseph Newell, Exec. VP (Age 52, Pay $670.38k) (LinkedIn Profile)
  • Dr. Kristin Yarema Ph.D., SVP & Chief Commercial Officer (Age 51, Pay $700.67k)
  • Dr. Jakob Dupont M.D., Exec. VP and Global Head of R&D (Age 57, Pay $595.87k)
  • Ms. Charlene Banard, Chief Technical Officer (Age 59)
  • Dr. Anhco Nguyen, Chief Scientific Officer (Age 49)
  • Eric Hyllengren, VP of Investor Relations & Fin.
  • Mr. K. Amar Murugan, Sr. VP & Gen. Counsel (Age 47) (LinkedIn Profile)
  • Kerry Beth Daly, Head of Corp. Communications
What is Pascal Touchon's approval rating as Atara Biotherapeutics' CEO?

6 employees have rated Atara Biotherapeutics CEO Pascal Touchon on Glassdoor.com. Pascal Touchon has an approval rating of 60% among Atara Biotherapeutics' employees. This puts Pascal Touchon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Atara Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atara Biotherapeutics investors own include CRISPR Therapeutics (CRSP), AbbVie (ABBV), Exelixis (EXEL), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), OPKO Health (OPK), Gilead Sciences (GILD), Micron Technology (MU) and Pfizer (PFE).

What is Atara Biotherapeutics' stock symbol?

Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."

Who are Atara Biotherapeutics' major shareholders?

Atara Biotherapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include JPMorgan Chase & Co. (8.77%), Baupost Group LLC MA (8.70%), BlackRock Inc. (8.35%), Vanguard Group Inc. (7.40%), State Street Corp (6.72%) and Wasatch Advisors Inc. (4.09%). Company insiders that own Atara Biotherapeutics stock include Amar Murugan, Jakob Dupont, Joe Newell, Kristin Yarema, Matthew K Fust, Pascal Touchon, Thomas Peterffy and Utpal Koppikar.
View institutional ownership trends for Atara Biotherapeutics
.

Which institutional investors are selling Atara Biotherapeutics stock?

ATRA stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Artal Group S.A., Baupost Group LLC MA, Vanguard Group Inc., Citigroup Inc., PDT Partners LLC, Canada Pension Plan Investment Board, and M28 Capital Management LP. Company insiders that have sold Atara Biotherapeutics company stock in the last year include Amar Murugan, Jakob Dupont, Joe Newell, Matthew K Fust, Pascal Touchon, and Utpal Koppikar.
View insider buying and selling activity for Atara Biotherapeutics
or view top insider-selling stocks.

Which institutional investors are buying Atara Biotherapeutics stock?

ATRA stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Wasatch Advisors Inc., Goldman Sachs Group Inc., JPMorgan Chase & Co., Renaissance Technologies LLC, Eminence Capital LP, Ensign Peak Advisors Inc, and Sector Gamma AS.
View insider buying and selling activity for Atara Biotherapeutics
or or view top insider-buying stocks.

How do I buy shares of Atara Biotherapeutics?

Shares of ATRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Atara Biotherapeutics' stock price today?

One share of ATRA stock can currently be purchased for approximately $5.16.

How much money does Atara Biotherapeutics make?

Atara Biotherapeutics has a market capitalization of $481.97 million and generates $20.34 million in revenue each year. The biotechnology company earns $-340.14 million in net income (profit) each year or ($3.640010) on an earnings per share basis.

How many employees does Atara Biotherapeutics have?

Atara Biotherapeutics employs 578 workers across the globe.

What is Atara Biotherapeutics' official website?

The official website for Atara Biotherapeutics is www.atarabio.com.

How can I contact Atara Biotherapeutics?

Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at (650) 278-8930 or via email at [email protected].

This page was last updated on 5/19/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.